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muscle strength, ultrasound could be a useful tool for assessing disease severity
and monitoring disease progression in patients with PPS.
http://dx.doi.org/10.1016/j.rehab.2014.03.667
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Introduction.– Botulinum toxin (BTX) has long been used for the treatment of
spasticity. Currently, its indications have been enlarged to the musculoskeletal
system and particularly to the management of osteo-arthropathies.
Objectives.– Describe the effects of intramuscular and intra-articular BoNT-A
in painfull arthropathies in PRM.
Method.– Literature review.
Results.– Literature data report that intramuscular injection of BoNT-A may
represent an alternative for the management of reactive periarticular muscle
contractures after joint replacement surgery or of agonist/antagonist muscle
imbalance. The literature also reports some controlled randomized studies show-
ing the higher analgesic effect of BoNT-A intra-articular injections compared to
corticosteroids in chronic knee pain,chronic shoulder joint pain due to osteoar-
ticular conditions or rheumatoid arthritis, sacroiliac joint pain and refractory
pain after knee arthroplasty.
The effects of BoNT-A intra-articular injection have been investigated in animal
models and suggests that BoNT-A slows may have a chondroprotective effect by
limiting the alterations of the cartilage structures associated to analgesic effects
through inhibition of pain mediators.
Conclusions.– BoNT-A represents an interesting therapeutic alternative both for
intramuscular injection in case of periarticular muscle contractures and for intra-
articular injection, although its intra-articular effects need to be better defined
by further studies.
Further reading
Singh JA, et al. Transl Res 2009;153:205–16.
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Introduction.– Palmar hyperhidrosis is a disease that has substantial impact upon
affective, workplace and social relationships. This study aims to review the
existing evidences about the effectiveness of botulinum toxin in the treatment of
palmar hyperhidrosis and the role of iontophoresis as a drug delivery method.
Material and methods.– The expression “botulinum toxin” AND “palmar hyper-
hidrosis” AND “iontophoresis” was searched on PubMed, Cochrane and PEDro
databases. Articles were chosen for full text reading by abstract evaluation.
Results.– Botulinum toxin type A is a valid treatment option in patients with
severe sweating who have not responded to topical treatments. Benefits of using
botulinum toxin type A to inhibit palmar hyperhidrosis were documented in
several studies, however palmar injections are very painful. Previous studies
demonstrate that botulinum toxin type A can be effectively delivered to the
palms by iontophoresis.
Discussion.– Palmar hyperhidrosis can limit the patients’ quality of life.
Botulinum toxin type A iontophoresis is a non-invasive, inexpensive, safe and
effective treatment option for palmar hyperhidrosis. Considering the established
evidences, it is important to revise this unlabeled use.
Further reading
Andrade PC. Ann Bras Dermatol 2011;86:1243–6.
Choi YH. Dermatol Surg 2013;39:578–83.
Davarian S. Australas J Dermatol 2008;49:75–9.
http://dx.doi.org/10.1016/j.rehab.2014.03.669
CO18-005-e
Efﬁcacy of transcutaneous electrical nerve
stimulation (TENS) and kinesiotaping in
patients with lateral epicondylitis
G. Sari a,∗, S. Kanyilmaz a, H. Telli a, B. Huner a,
N. Yaraman a, G. Ozturk b, B. Kuran c
a Department of Physical Medicine and Rehabilitation, Okmeydani Education
and Research Hospital, Istanbul, Turkey
b Department of Physical Medicine and Rehabilitation, Yeditepe University
Hospital, Istanbul, Turkey
c Department of Physical Medicine and Rehabilitation, Sisli Etfal Education
and Research Hospital, Istanbul, Turkey
∗Corresponding author.
Keywords: Lateral epicondylitis; Tennis elbow; Transcutaneous electrical
nerve stimulation; Kinesiotaping
Introduction.– The aim of this study was to determine and compare the efficacy
of TENS and kinesiotaping in lateral epicondylitis (LE).
Methods.– In this prospective-randomised, assessor blinded controlled trial, sev-
enty eight patients were enrolled. Patients were allocated into 4 treatment groups:
Group 1 received TENS and kinesiotaping (KT), group 2 received TENS + sham
KT, group 3 received sham TENS + KT and group 4 received sham TENS + sham
KT. TENS was applied for 10 sessions and KT for 4 times in 10 days. Outcome
measures were pain-free grip strength, pressure pain threshold, pain severity
and patient rated tennis elbow evaluation for functional status. Patients were
assessed at randomization, on day 10 and at 12th week of follow-up.
Results.– On day 10, TENS, KT combination treatments were statistically supe-
rior to sham group (P < 0.05). At week 12, all groups had statistically significant
improvements compared to pre-treatment, however there were no significant
differences among groups.
Discussion.– To our knowledge, this is the first study that evaluates TENS and
KT in LE. In this study we found that KT alone or in combination with TENS
was not superior to TENS, sham TENS or sham KT. Further research is needed
to confirm these results.
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Introduction.– Only sparse evidence exists regarding the effectiveness of oral
alendronate in the prevention of heterotopic ossification in patients with spinal
cord injury. The objective is to investigate the protective effect of oral alendronate
intake on the appearance of heterotopic ossification (HO) in patients with spinal
cord injury (SCI).
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Methods.– The incidence of heterotopic ossification during rehabilitation was
compared between SCI patients receiving oral alendronate (n = 125) and SCI
patients not receiving oral alendronate (n = 174) in a retrospective database
review. The association between heterotopic ossification and/or alendronate
intake with HO risk factors and biochemical markers of bone metabolism were
also explored.
Results.– HO developed in 19 male patients (6.35%), however there was no sig-
nificant difference in the incidence of HO in patients receiving oral alendronate
or not. Significant correlation was found between abnormal serum alkaline phos-
phatase levels and HO appearance (P < 0.001) as well as normal serum alkaline
phosphatase and alendronate intake (P < 0.05).
Discussion.– Even though there was no direct prevention of heterotopic ossi-
fication in SCI patients by oral alendronate intake, abnormal serum alkaline
phosphatase was found more frequently in patients with HO development and
without oral alendronate intake. This evidence suggests that alendronate may
play a role in preventing HO.
http://dx.doi.org/10.1016/j.rehab.2014.03.671
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Introduction.– NSAIDs are very prescribed drugs, used mainly as painkillers in
musculoskeletal disease. They have important contraindications, standing out
theircardiovascular risk. Current evidence suggests that there is no cardiovas-
cularly safe NSAID, being naproxen the least harmful. Their careful use is
important in the elderly, since cardiovascular disease is one of their main causes
of morbidity and mortality. Our objective was to evaluate NSAIDs prescription
in elderly with musculoskeletal disease and their cardiovascular risk.
Material and methods.– Cross-sectional observational study, held on a Por-
tuguese Health Centre, in half of patients between 65 and 84-years-old, randomly
selected, who had a consultation from 1 to 17/January/2013. Data collected from
electronic clinical process and statistically analyzed.
Results.– In a sample of 318 patients, 23.6% (n = 75) had NSAIDs prescribed,
48.0% (n = 36) of them due to musculoskeletal disease. Of these, 80.6% (n = 29)
had increased cardiovascular risk, whom 37.9% (n = 11) had naproxen pre-
scribed.
Discussion.– NSAIDs are very used in elderly with musculoskeletal disease
and most of them have increased cardiovascular risk. Naproxen is already quite
used. There is need to improve analgesic prescription in elderly patients, by
increasing naproxen use and by replacing NSAIDs with other “painkillers” –
physical agents, rehabilitation programs and regular exercise.
http://dx.doi.org/10.1016/j.rehab.2014.03.672
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Objective.– To determine the relationship between sacroiliac joint (SIJ) contrast
dispersal patterns during SIJ injection and pain relief at 2 weeks and 2 months
post-procedure.
Methods.– A retrospective review of medical records identified patients who
underwent therapeutic SIJ corticosteroid injection. Fluoroscopic contrast flow
patterns were categorized as type I (cephalad extension within SIJ) or type II
(minimal cephalo extension with inferior extravasation). Self-reported (NPRS)
values at the time of injection and 2 and 8 weeks post-procedure were recorded.
Main outcome measures: the primary outcome measure was effect of type of con-
trast pattern on change in NPRS values at 2 weeks and 2 months post-injection.
The secondary outcome measure was association between number of positive
provocative SIJ physical examination maneuvers and decrease in level of pain
following the procedure.
Results.– All subjects had decreased NPRS values at 2 and 8 weeks compared
to baseline. Subjects with type I flow had greater reductions in pain at 2 and
8 weeks compared to those with type II flow.
Conclusions.– Fluoroscopically guided corticosteroid injections into the SIJ
joint are effective in decreasing NPRS values in patients with SIJ-mediated
pain. Intra-articular delivery of corticosteroid to the SIJ leads to more favourable
clinical outcomes.
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Purpose.– To analyze the change in utilization of various steroids in cervical
and lumbar transforaminal epidural steroid injections (TFESI), with a focus on
non-particulate versus particulate steroid.
Materials and methods.– The Lifeline IMS Health database containing outpa-
tient billing claims from 1/1/2012 to 12/31/2012 representing over 61 million
lives was interrogated and a dataset was generated based on the following:
commercial insurance claims on subjects under age 65 undergoing TFESI.
Results.– Steroid use in cervical (TFESI) changed from betamethasone in 2002
to dexamethasone in 2012. The most commonly used steroids for cervical TFESI
in 2012 were dexamethasone (17.57%), methylprednisolone (12.84%) and tri-
amcinolone (6.08%). Compounded steroid use changed from 2.04% in 2002 to
0.68% in 2012. The mostly commonly used steroids for lumbar TFESI in 2012
were methylprednisolone (19.70%), triamcinolone (11.15%) and dexametha-
sone (6.16%). Compounded steroids were used in 0.42% of procedures in 2002
and 2.07% in 2012.
Discussion.– Over the past decade, there has been a trend toward utilization
of non-particulate steroids, particularly with cervical transforaminal epidural
steroid injections. The data show a changing standard of care from particulate
to non-particulate steroids, particularly with cervical transforaminal epidural
steroid injections.
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Introduction.– Sever disease refers to a calcaneal apophysitis. It is a nonarticular
osteochondrosis of the calcaneal apophysis, which occurs in children and young
adolescents. Sever disease is the most common cause of heel pain in the growing
child. But there are not so much documentary about this condition so this case
highlights the clinical features of this self-limiting disorder.
Observation.– We report a 12-year-old male presented in our out patient clinic
with a 3 month history of bilateral heel pain. Pain had worsened over a 2-week
period and at times, he walked on his toes. The pain was of spontaneous onset
with no history of trauma. The pain was aggravated by activity and relieved
